Hepatitis C Re-treatment with Interferon Monotherapy Provides Little Benefit
- Details
- Category: HCV Treatment
- Published on Wednesday, 06 February 2013 00:00
- Written by Liz Highleyman
Long-term re-treatment with pegylated interferon monotherapy offers little or no clinical benefit -- even though it may suppress hepatitis C virus (HCV) levels and improve liver fibrosis -- but it can cause adverse events and may be associated with higher mortality, according to a systematic review from the Cochrane Library.
More Articles...
- HIV+ People Who Get Hepatitis C May Experience Rapid Liver Disease Progression
- Hepatitis C Cirrhosis Patients with Sustained Treatment Response Have Lower Risk of Death
- Coverage of the 2012 AASLD Liver Meeting
- Hepatitis C Raises Risk of Both Liver-Related and Non-Liver Deaths
- FibroScan Liver Stiffness Measurement Predicts Liver Failure and Death
Web Design and Development by